Patents by Inventor Mathias Scheer
Mathias Scheer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210059944Abstract: The present invention relates to a solid oral pharmaceutical dosage form with a novel and well defined order of specific coatings allowing for the very defined and controlled release of at least one pharmaceutical active ingredient (API) and a broad range of potential uses. Particularly, the dosage form according to the invention comprises an immediate release active core, a first delayed-release layer comprising an enteric coating, a second sustained release layer comprising a retard polymer, and a third immediate release layer comprising an active pharmaceutical ingredient. The solid oral pharmaceutical dosage form as such is characterized in having a bi-modal release profile of the at least one API with a much less variable second delayed release than known prior art pharmaceutical compositions, allowing for the application of different APIs or combinations thereof in for a variety of indications.Type: ApplicationFiled: March 8, 2018Publication date: March 4, 2021Inventors: Mathias Scheer, Helene Rey
-
Patent number: 9387166Abstract: The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.Type: GrantFiled: June 29, 2012Date of Patent: July 12, 2016Assignee: DEVELCO PHARMA SCHWEIZ AGInventors: Hélène Rey, Marc Fischer, Mathias Scheer, Dirk Kramer
-
Publication number: 20140377349Abstract: The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.Type: ApplicationFiled: June 29, 2012Publication date: December 25, 2014Applicant: DEVELCO PHARMA SCHWEIZ AGInventors: Hélène Rey, Marc Fischer, Mathias Scheer, Dirk Kramer
-
Patent number: 8709477Abstract: This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate.Type: GrantFiled: August 13, 2010Date of Patent: April 29, 2014Assignee: Kremers Urban Pharmaceuticals, Inc`Inventors: Dirk Kramer, Helene Rey, Mathias Scheer
-
Publication number: 20120189695Abstract: This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate.Type: ApplicationFiled: August 13, 2010Publication date: July 26, 2012Applicant: Kudco Ireland LtdInventors: Dirk Kramer, Helene Rey, Mathias Scheer
-
Publication number: 20110201633Abstract: A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.Type: ApplicationFiled: March 17, 2011Publication date: August 18, 2011Applicant: ACINO PHARMA AGInventors: Mathias SCHEER, Michel KELBERT
-
Publication number: 20090270448Abstract: Melt granulate in the form of a solid state dispersion of the drug in a pharmaceutically acceptable carrier, wherein said melt granulate comprises a pharmaceutically active compound, preferably clopidogrel, at least one carrier material, and optionally pharmaceutically acceptable excipients and method of making said melt granulate.Type: ApplicationFiled: September 17, 2007Publication date: October 29, 2009Applicant: ACINO PHARMA AGInventors: Helene Rey, Marc Fischer, Mathias Scheer
-
Publication number: 20060062846Abstract: A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride anhydrate, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.Type: ApplicationFiled: May 6, 2005Publication date: March 23, 2006Applicant: Cimex Pharma AGInventors: Mathias Scheer, Helene Rey, Marc Fischer, Dirk Kramer
-
Publication number: 20060062845Abstract: A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.Type: ApplicationFiled: September 17, 2004Publication date: March 23, 2006Applicant: CIMEX Pharma AGInventor: Mathias Scheer